$31.73
▼ -21.2% Today
as of Oct 22, 16:51 ET
Last 30 days
Recent Press Releases & News
Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development
Quince Therapeutics Changes Name to IRulya Therapeutics
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
QNCX earnings at a glance
Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±5.4% on average; after the most recent report on May 11, 2026 it moved -3.1%. QNCX beat the consensus EPS estimate in 0 of its last 3 reported quarters. The share price of $31.73 sits near its 52-week low.
Overview
52-week range
$15
$910
2% of range
Avg surprise (last 3)
-29.4%
Avg reaction (last 2)
-5.4%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-12.31 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.59 | — | — | -73.5% | -3.1% | earnings |
| Wed Nov 12, 2025 | Sep/2025 | $-0.25 | $-0.20 | -25.0% | — | — | earnings |
| Mon Aug 11, 2025 | Jun/2025 | $-0.34 | $-0.28 | -21.4% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.34 | $-0.24 | -41.7% | — | -7.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.64 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.26 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.34 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-80M | $-15M | — | $-13M | $-10M | $-15M | — | $-6M |
| Net income | $-75M | $36M | — | $-13M | $-16M | $-15M | — | $-5M |
| EPS (diluted) | $-12.31 | $2.88 | — | $-0.25 | $-68.75 | $-3.42 | — | $-0.13 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $116M | $18M | $6M | $6M | $17M | $8M | $6M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $123M | $26M | $23M | $29M | $37M | $34M | $44M | $52M |
| Total assets | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M |
| Long-term debt | — | — | — | $0 | $17M | $15M | $14M | $15M |
| Total liabilities | $16M | $11M | $129M | $109M | $105M | $89M | $84M | $82M |
| Total equity | $-35M | $16M | $-36M | $1M | $12M | $19M | $30M | $45M |
Implied volatility — last 90 days
No IV snapshots yet for QNCX.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
QNCX earnings FAQ
How does QNCX stock usually react to earnings?
Across the last 2 reports the average next-day move was ±5.4%, up 0 times and down 2 times.